These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38843966)

  • 21. TP53 alterations of hormone-naïve prostate cancer in the Chinese population.
    Liu Z; Guo H; Zhu Y; Xia Y; Cui J; Shi K; Fan Y; Shi B; Chen S
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):482-491. PubMed ID: 33214693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
    Millis SZ; Jardim DL; Albacker L; Ross JS; Miller VA; Ali SM; Kurzrock R
    Cancer; 2019 Apr; 125(7):1185-1199. PubMed ID: 30582752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor Mutational Burden and Genomic Alterations in Chinese Small Cell Lung Cancer Measured by Whole-Exome Sequencing.
    Su S; Zou JJ; Zeng YY; Cen WC; Zhou W; Liu Y; Su DH; Zhang XL; Huang HY; Lei A; Huang ZH; Jin Y; Li L; Su N; Xie YL; Zhao ZG; Liu JX
    Biomed Res Int; 2019; 2019():6096350. PubMed ID: 31781628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of age at diagnosis on racial disparities in endometrial cancer patients.
    Tarney CM; Tian C; Wang G; Dubil EA; Bateman NW; Chan JK; Elshaikh MA; Cote ML; Schildkraut JM; Shriver CD; Conrads TP; Hamilton CA; Maxwell GL; Darcy KM
    Gynecol Oncol; 2018 Apr; 149(1):12-21. PubMed ID: 28800945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.
    Cani AK; Soliman M; Hovelson DH; Liu CJ; McDaniel AS; Haller MJ; Bratley JV; Rahrig SE; Li Q; Briceño CA; Tomlins SA; Rao RC
    Mod Pathol; 2016 Jul; 29(7):685-97. PubMed ID: 27102345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The molecular pathogenesis of Trichilemmal carcinoma.
    Ha JH; Lee C; Lee KS; Pak CS; Sun CH; Koh Y; Chang H
    BMC Cancer; 2020 Jun; 20(1):516. PubMed ID: 32493317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
    Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC
    Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
    Cloughesy TF; Yoshimoto K; Nghiemphu P; Brown K; Dang J; Zhu S; Hsueh T; Chen Y; Wang W; Youngkin D; Liau L; Martin N; Becker D; Bergsneider M; Lai A; Green R; Oglesby T; Koleto M; Trent J; Horvath S; Mischel PS; Mellinghoff IK; Sawyers CL
    PLoS Med; 2008 Jan; 5(1):e8. PubMed ID: 18215105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PI3K/AKT pathway activation in bladder carcinogenesis.
    Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
    Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment.
    Song HN; Lee C; Kim ST; Kim SY; Kim NK; Jang J; Kang M; Jang H; Ahn S; Kim SH; Park Y; Cho YB; Heo JW; Lee WY; Park JO; Lim HY; Kang WK; Park YS; Park WY; Lee J; Kim HC
    Oncotarget; 2016 Apr; 7(15):19610-9. PubMed ID: 26909603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.
    Keenan T; Moy B; Mroz EA; Ross K; Niemierko A; Rocco JW; Isakoff S; Ellisen LW; Bardia A
    J Clin Oncol; 2015 Nov; 33(31):3621-7. PubMed ID: 26371147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients.
    Kim Y; Hammerman PS; Kim J; Yoon JA; Lee Y; Sun JM; Wilkerson MD; Pedamallu CS; Cibulskis K; Yoo YK; Lawrence MS; Stojanov P; Carter SL; McKenna A; Stewart C; Sivachenko AY; Oh IJ; Kim HK; Choi YS; Kim K; Shim YM; Kim KS; Song SY; Na KJ; Choi YL; Hayes DN; Kim J; Cho S; Kim YC; Ahn JS; Ahn MJ; Getz G; Meyerson M; Park K
    J Clin Oncol; 2014 Jan; 32(2):121-8. PubMed ID: 24323028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients.
    Yoon HH; Shi Q; Alberts SR; Goldberg RM; Thibodeau SN; Sargent DJ; Sinicrope FA;
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26160882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of NRAS, PTEN and AKT1 gene mutations in the central nervous system metastases of non-small cell lung cancer.
    Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Trojanowski T; Milanowski J
    Brain Tumor Pathol; 2017 Jan; 34(1):36-41. PubMed ID: 28097440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
    Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
    Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014.
    Ostrom QT; Cote DJ; Ascha M; Kruchko C; Barnholtz-Sloan JS
    JAMA Oncol; 2018 Sep; 4(9):1254-1262. PubMed ID: 29931168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.
    Bettstetter M; Berezowska S; Keller G; Walch A; Feuchtinger A; Slotta-Huspenina J; Feith M; Drecoll E; Höfler H; Langer R
    Hum Pathol; 2013 May; 44(5):829-36. PubMed ID: 23158210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.